Skip to main content
Premium Trial:

Request an Annual Quote

Amgen, Selexis Expand Deal to Include Evaluation of Mammalian Cell Line

NEW YORK (GenomeWeb News) – Amgen expanded an R&D licensing agreement to include the evaluation of Selexis' Sure Cho-M Cell Line.

Under the terms of the deal announced today by Selexis, Amgen will assess the cell line in conjunction with the Selexis SUREtech Vectors for improved R&D. Sure Cho-M Cell Line is a mammalian cell line derived from CHO-K1 cells and is for producing therapeutic recombinant proteins and monoclonal antibodies.

Financial and other terms of the deal were not disclosed.

Today's announcement builds on a relationship between Selexis and Amgen reaching back to 2004, Igor Fisch, president and CEO of Selexis, said in a statement.

"Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding, and stable," he said. "Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently."

Based in Geneva, Selexis provides technologies for drug discovery, cell line development, and scale-up to manufacturing of therapeutic proteins.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.